Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
RESEARCH TOOLSreports
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$189.00 - $377.46
Previous CloseN/A
Volume47.78K
Average Volume (3M)422.47K
Market Cap
$7.54B
Enterprise Value$3.73B
Total Cash (Recent Filing)$47.49M
Total Debt (Recent Filing)$900.00K
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 13, 2025EPS Estimate
-3.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.11
Shares Outstanding22,080,246
10 Day Avg. Volume429,174
30 Day Avg. Volume422,470
Standard Deviation0.44
R-Squared0.00206
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)41.15
Price to Cash Flow (P/CF)-17.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.08K
Enterprise Value/Ebitda-7.42
Forecast
1Y Price Target
$413.27Price Target Upside21.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRezdiffra product sales revenue was $103.3M, which beat expectations of $100M, and represents 66% sequential growth.
Market StrategyRezdiffra's penetration gains have been better than expected due to effective launch tactics.
Bears Say
Market RisksPotential headwinds include how payers will manage greater patient numbers and the impact of GLP-1s on uptake and pricing.
---
Ownership Overview
19.56% Insiders
27.43% Mutual Funds
0.07% Other Institutional Investors
38.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $189.00 and its highest was $377.46 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $7.54B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is May 13, 2025 which is in 70 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Feb 26, 2025. The company reported -$2.71 earnings per share for the quarter, beating the consensus estimate of -$3.92 by $1.21.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -3.78.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 22,080,246 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$2.71 in its last earnings report, beating expectations of -$3.92. Following the earnings report the stock price went up 14.989%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
---
Madrigal Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$413.27 (21.10% Upside)
$413.27 (21.10% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 160.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.7%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.23%
12-Months-Change
Fundamentals
Return on Equity
-80.35%
Trailing 12-Months
Asset Growth
62.71%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
MDGL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Madrigal Pharmaceuticals demonstrated strong performance with the successful launch of Rezdiffra, significant prescriber engagement, and promising clinical data. Despite rising expenses and market challenges, the company's financial health and strategic positioning remain robust.Read More>---
MDGL Stock 12 Month Forecast
Average Price Target
$413.27
▲(21.10% Upside)
Technical Analysis
Altimmune
―
Galectin Therapeutics
―
Galmed Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+81.20%
reiterated a buy rating 5 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +81.20% per trade.
---